Adjuvant Treatment for Uterine Sarcomas

1. Uterine Leiomyosarcoma (LMS) — Most common (~60%)

Localized Disease (FIGO Stage I)

• Adjuvant chemotherapy is not the standard of care for stage I disease (ESGO/EURACAN/GCIG 2024, evidence level IV–V, Grade C).
• However, it can be considered in patients at high risk of relapse after shared decision-making — particularly with tumor rupture or morcellation.
• Regimens used in trials: gemcitabine + docetaxel (Hensley et al., Gynecol Oncol 2009; prospective phase II, stages I–IV, 4-year PFS ~57% for stage I–II) and doxorubicin-based regimens.
• Adjuvant radiotherapy is not recommended for localized LMS — there is no evidence of survival benefit, though it may improve local control. It is not standard (ESGO/EURACAN/GCIG Grade C; NCCN 2025).

Locally Advanced Disease (FIGO Stages II–III)

• Chemotherapy (gemcitabine + docetaxel or doxorubicin ± ifosfamide) can be considered after complete resection.
• Radiotherapy may provide local control but does not improve overall survival; it is not standard.

Key point on morcellation

2. Low-Grade Endometrial Stromal Sarcoma (LG-ESS) — ~20%

Stage I — adjuvant systemic therapy

• Adjuvant endocrine therapy is NOT recommended for stage I LG-ESS (ESGO/EURACAN/GCIG 2024, Grade D).
• BSO (bilateral salpingo-oophorectomy) is recommended at the time of hysterectomy to eliminate endogenous estrogen.
• Tamoxifen is contraindicated (estrogenic effects on ER+ tumor).

Stages II, III–IV — post-operative endocrine therapy

• Post-operative endocrine therapy can be considered for completely resected stage II–IV ER/PR-positive LG-ESS:
  • Aromatase inhibitors: anastrozole, letrozole, or exemestane (preferred)
  • Progestins: megestrol acetate or medroxyprogesterone acetate
• In case of morcellation, consideration should be given to post-operative endocrine therapy due to greater risk of dissemination (ESGO Grade C–D).

Radiotherapy

• Adjuvant radiotherapy is NOT recommended for any stage of LG-ESS (ESGO Grade D).

3. High-Grade Endometrial Stromal Sarcoma (HG-ESS) and Undifferentiated Uterine Sarcoma (UUS)

FIGO Stages I–III

• Adjuvant chemotherapy is not the standard of care for stage I HG-ESS/UUS.
• It could be considered in patients at high risk of relapse, after discussion (ESGO Grade C).
• In case of morcellation, post-operative chemotherapy should be considered due to very high relapse risk (ESGO Grade C).
• Adjuvant radiotherapy is not standard after hysterectomy for localized disease; it could be considered based on local recurrence risk (ESGO Grade C).

Regimens used:

• Doxorubicin-based (doxorubicin ± ifosfamide)
• Gemcitabine + docetaxel

4. Adenosarcoma

Stage I

• Adjuvant chemotherapy is not recommended for stage I adenosarcoma without sarcomatous overgrowth (ESGO 2024).
• BSO is preferred (added to NCCN v1.2025 for low-grade ESS or adenosarcoma without sarcomatous overgrowth).
• Adjuvant radiotherapy is not recommended for stage I (ESGO Grade C).

Stages II–IV (or with sarcomatous overgrowth/high-grade component)

• Adjuvant chemotherapy can be considered for completely resected stage II, III–IV adenosarcoma due to poor prognosis (ESGO Grade C).
• If morcellated with a high-grade component or sarcomatous overgrowth, post-operative chemotherapy could be considered (ESGO Grade D).
• Post-operative radiotherapy could be considered for stage II–IV for local control, though there is no evidence of survival benefit.

5. Carcinosarcoma (MMMT) — Managed as High-Grade Carcinoma

• Adjuvant chemotherapy: Carboplatin + paclitaxel is the standard (preferred by NCCN 2025 and ESGO endometrial guidelines). This is the foundation of adjuvant therapy, especially for extrauterine disease.
• Pembrolizumab + carboplatin/paclitaxel and dostarlimab regimens have been recently added to NCCN as options for eligible patients.
• Radiotherapy (pelvic EBRT ± brachytherapy) is added for local control in higher stages.
• GOG 184 trial showed that adding paclitaxel to cisplatin + doxorubicin + radiation did not improve 3-year survival over the 2-drug regimen.

Summary Table

Key Chemotherapy Regimens Referenced

• Berek & Novak's Gynecology (16th ed.), Chapter 37
• ESGO/EURACAN/GCIG Guidelines for Uterine Sarcomas 2024 — Ray-Coquard et al., Int J Gynecol Cancer 2024;34(10):1499–1521 + ESGO 2025 Pocket Guidelines
• NCCN Guidelines Uterine Neoplasms Version 1.2025